原发性骨质疏松症诊治思考

doi:10.6040/j.issn.1671-7554.0.2021.0247

摘要/Abstract

摘要： 我国即将快速进入老龄社会,骨质疏松骨折严重威胁老年人生命及生活质量,给家庭和社会造成严重负担。对骨质疏松症认知水平的提高及对其诊治过程细节的了解和掌握将有助于更精准的完成诊疗,从而更有效地降低骨质疏松骨折风险。

Abstract: With the emerging era of aging in China, osteoporotic fracture has adversely affected the health and quality of life of the elderly population, bringing huge burden to families and society. Raising awareness of osteoporosis, and understanding the diagnosis and management will greatly help doctors achieve better disease control and reduce the risk of osteoporotic fracture.

Key words: Osteoporosis, Diagnosis, Management

中图分类号:

R681

邢小平. 原发性骨质疏松症诊治思考[J]. 山东大学学报 (医学版), 2021, 59(6): 1-4.

XING Xiaoping. Diagnosis and management of primary osteoporosis[J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 1-4.

参考文献

[1] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 25(3): 413-443. Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and treatment of primary osteoporosis(2017)[J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2017, 25(3): 413-443.
[2] Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 Update [J]. Endocr Pract, 2020, 26(Suppl 1): 1-46.
[3] Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women [J]. Osteoporos Int, 2013, 24(1): 23-57.
[4] Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures [J]. Osteoporos Int, 2020, 31(1): 1-12.
[5] 夏维波. 骨质疏松症高骨折风险患者的识别与防治策略[J]. 中华骨质疏松和骨矿盐疾病杂志, 2020, 13(6): 493-498. XIA Weibo. Identification and management strategies for osteoporosis patients with high fracture risk [J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2020, 13(6): 493-498.
[6] Cui L, He T, Jiang Y, et al. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data [J]. Osteoporos Int, 2020, 31(2): 307-316.
[7] Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis [J]. J Clin Endocrinol Metab, 2019, 104(5): 1623-1630.
[8] Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society^* clinical practice guideline [J]. J Clin Endocrinol Metab, 2019, 104(5): 1595-1622.
[9] Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension(FLEX): a randomized trial [J]. JAMA, 2006, 296(24): 2927-2938.
[10] Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial(Pft)[J]. J Bone Miner Res, 2012, 27(2): 243-254.
[11] Anastasilakis AD, Polyzos SA, Yavropoulou MP, et al. Combination and sequential treatment in women with postmenopausal osteoporosis [J]. Expert Opin Pharmacother, 2020, 21(4): 477-490.
[12] Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study): Extension of a randomised controlled trial [J]. Lancet, 2015, 386(9999): 1147-1155.
[13] Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial [J]. J Bone Miner Res, 2018, 33(5): 783-794.
[14] Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches [J]. Bone, 2020, 139: 115516. doi:10.1016/j.bone.2020.115516.

相关文章 15

[1]	李波波李道堂刘曙光王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61.
[2]	徐平于国放李霞. 不同类型甲状腺上动脉PSV对Graves病与桥本氏甲状腺炎鉴别诊断的价值[J]. 山东大学学报(医学版), 2209, 47(6): 62-64.
[3]	王欣，邢春燕，杨艳平. 血清磷酸丙酮酸水合酶检测对诊断侵袭性白念珠菌感染的临床价值[J]. 山东大学学报(医学版), 2209, 47(6): 92-94.
[4]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[5]	山东省医学会心电学分会山东省医学伦理学学会心电学分会. 心电图报告规范化书写专家共识(2026)[J]. 山东大学学报 (医学版), 2026, 64(4): 1-7.
[6]	孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62.
[7]	林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[8]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[9]	中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10.
[10]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[11]	罗淇,王霞,姜孟. 脑功能网络分析在失语症诊疗中的应用:病理机制分析、临床诊断与疗效评价[J]. 山东大学学报 (医学版), 2025, 63(8): 111-126.
[12]	河南省生物医学工程学会立体心电图专业委员会,中国医药教育协会心电学专业委员会,山东中医药学会心电学专业委员会,青岛市医学会心电生理与起搏专科分会,全国医药技术市场协会远程心脏专业委员会. 心电向量图诊断标准规范化专家共识(2025)[J]. 山东大学学报 (医学版), 2025, 63(7): 1-10.
[13]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[14]	祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88.
[15]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed